Response to neoadjuvant targeted therapy in operable head and neck cancer confers survival benefit

MLA

Marco A. Mascarella, et al. “Response to Neoadjuvant Targeted Therapy in Operable Head and Neck Cancer Confers Survival Benefit.” European Journal of Cancer, vol. 174, Oct. 2022, p. S128. EBSCOhost, https://doi.org/10.1016/s0959-8049(22)01141-8.

APA

Marco A. Mascarella, Tolani F. Olonisakin, Purva Rumde, Varun Vendra, Melonie A. Nance, Seungwon Kim, Mark W. Kubik, Shaum S. Sridharan, Robert L. Ferris, Moon J. Fenton, Daniel R. Clayburgh, James P. Ohr, Sonali C. Joyce, Malabika Sen, James G. Herman, Jennifer R. Grandis, Dan P. Zandberg, & Umamaheswar Duvvuri. (2022). Response to neoadjuvant targeted therapy in operable head and neck cancer confers survival benefit. European Journal of Cancer, 174, S128. https://doi.org/10.1016/s0959-8049(22)01141-8

Chicago

Marco A. Mascarella, Tolani F. Olonisakin, Purva Rumde, Varun Vendra, Melonie A. Nance, Seungwon Kim, Mark W. Kubik, et al. 2022. “Response to Neoadjuvant Targeted Therapy in Operable Head and Neck Cancer Confers Survival Benefit.” European Journal of Cancer 174 (October): S128. doi:10.1016/s0959-8049(22)01141-8.